Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.

Follo, My; Pellagatti, A; Armstrong, Rn2; Ratti, S3; Mongiorgi, S3; De Fanti, S4; Bochicchio, Mt5; Russo, D; Gobbi, M7; Miglino, M7; Parisi, S5; Martinelli, G8; Cavo, M; Luiselli, D9; Mccubrey, Ja10; Suh, Pg11; Manzoli, L3; Boultwood, J2; Finelli, C5; Cocco, L12.